<DOC>
	<DOCNO>NCT00209833</DOCNO>
	<brief_summary>This randomized phase II/III trial investigates antileukemic activity toxicity FLAG-Ida regimen second induction course patient acute myeloid leukaemia bad response first induction cycle and/or high risk karyotype compare antileukemic activity toxicity high dose cytarabine/daunorubicin vs. autologous peripheral blood stem cell transplantation late consolidation therapy standard risk patient .</brief_summary>
	<brief_title>Treatment Adults Aged Up 60 Years With De Novo Acute Myeloblastic Leukaemia , Secondary AML , RAEB-T</brief_title>
	<detailed_description>Assessment antileukemic activity toxicity FLAG-Ida regimen second induction course patient bad response first induction cycle and/or high risk karyotype . Optimization late consolidation therapy standard risk patient ( SR ) prospective randomize trial compare high-dose cytarabine/daunorubicin ( HD-Ara-C/DNR ) base late consolidation therapy autologous peripheral blood stem cell transplantation ( PBSCT ) Assessment antileukemic activity different treatment element monitor residual disease ( MRD ) induction , early late consolidation Real-time PCR Assessment prognostic relevance minimal residual disease quantification residual leukemic burden haematological remission Real-time PCR follow-up</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>diagnosis denovo AML , FAB M 1 , 2 , 4 7 diagnosis secondary AML chemo/radiotherapy MDS diagnosis RAEBT age 16 60 year ( include 60 year ) woman exclusion pregnancy write informed consent patient severe disease heart ( e.g . cardial failure NYHA III/IV ; history myocardial infarction within last 6 month ; severe ventricular arrythmias ( Lown III IV ) patient DLCO &lt; 50 % patient creatinine clearance &lt; 60 ml/min patient bilirubin &gt; 2mg % ( 34.2 mmol/L ) patient severe complication leukaemia uncontrolled bleeding , pneumonia hypoxia shock patient psychiatric , addictive , disorder compromise ability give truly informed consent participate study HIV positivity patient ( 15 ; 17 ) translocation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>